Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 5/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.40 |
| ▸ | WNT3A | P56704 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | EPM2A | O95278 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419257 | 0.86 | HTR1B (0.44) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL7788846 | 0.82 | ABL1 (0.47) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL1116477 | 0.79 | HTR1B (0.49) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL2578196 | 0.77 | CYP2A6 (0.42) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| Hydrochloric Acid SCHEMBL27927457 | 0.75 | ALDH1A1 (0.52) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL24783507 | 0.75 | CYP2A6 (0.46) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL13153074 | 0.75 | CYP2A6 (0.46) | HTR1BCYP2A6DYRK1ACTNNB1WNT3A | |
| SCHEMBL6001072 | 0.75 | CYP2A6 (0.46) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL11355784 | 0.75 | DYRK1A (0.46) | HTR1BCYP2A6CA2DYRK1ACTNNB1 | |
| SCHEMBL14635442 | 0.74 | CYP2A6 (0.46) | HTR1BCYP2A6CA2DYRK1ACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-0152340-B1 | 2-Sulfamoylbenzo[b]furan derivatives and ophtalmic composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4544667-A | CARBONIC ANHYDRASE INHIBITOR; VISION DEFECTS | MERCK & CO., INC. (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0152340-A1 | 2-Sulfamoylbenzo[b]furan derivatives and ophtalmic composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | HTR1B 107/4885CYP2A6 753/4885CA2 4007/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | HTR1B 107/4885CYP2A6 753/4885CA2 4007/4885 |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | HTR1B 107/4885CYP2A6 753/4885CA2 4007/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | HTR1B 1211/4885CYP2A6 1509/4885CA2 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.